Objective  To explore the clinical efficacy of edaravone dexborneol combined with intravenous thrombolysis with alteplase, in the treatment of patients with acute ischemic stroke (AIS).

Methods  The patients with AIS undergoing intravenous thrombolysis with alteplase between January 7, 2021 and December 31, 2022 were enrolled  and randomly divided into observation group and control group. The control group was treated with standard treatment according to the AIS guidelines, and the observation group was treated with edaravone dexborneol injection within 48 hours from thrombolysis to the onset of the disease on the basis of the treatment in the control group. 7-day post-thrombolysis National Institutes of Health stroke scale (NIHSS), discharged NIHSS, difference between 7-day post-thrombolysis NIHSS and pre-thrombolysis NIHSS, and 3-month all-cause mortality and 3-month poor prognosis ratio were compared between the two groups.

Results  A total of 232 patients  with AIS were randomly allocated to the observation group (n=116) and the control group (n=116). The differences between the two groups were not statistically significant for 7-day post-thrombolysis NIHSS and difference between 7-day post-thrombolysis NIHSS and pre-thrombolysis NIHSS (P>0.05), and there were statistical differences in distribution of the discharged NIHSS score between the observation group and control group [2.0 (0, 3.0) vs. 2.0 (1.0, 5.0), P<0.05]. The 3-month poor prognosis ratio was significantly lower in the observation group than in the control group (12.1% vs. 28.4%; OR=0.252, 95%CI 0.105 to 0.602 , P=0.002).

Conclusion  Edaravone dexborneol enhances the efficacy of AIS undergoing intravenous thrombolysis with alteplase and improves the 3-month outcome of patients.

1.《中国脑卒中防治报告》编写组. 《中国脑卒中防治报告2020》概要[J]. 中国脑血管病杂志, 2022, 19(2): 136-144. DOI: 10.3969/j.issn.1672-5921.2022.02.011.

2.Tu WJ, Wang LD, Special Writing Group of China Stroke Surveillance Report. China stroke surveillance report 2021[J]. Mil Med Res, 2023, 10(1): 33. DOI: 10.1186/s40779-023-00463-x.

3.中国医师协会神经内科医师分会脑血管病学组. 急性脑梗死缺血半暗带临床评估和治疗中国专家共识[J]. 中国神经精神疾病杂志, 2021, 47(6): 324-335. DOI: 10.3969/j.issn.1002-0152.2021.06.002.

4.Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials[J]. Lancet, 2014, 384(9958): 1929-1935. DOI: 10.1016/S0140-6736(14)60584-5.

5.Qin C, Yang S, Chu YH, et al. Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions[J]. Signal Transduct Target Ther, 2022, 7(1): 215. DOI: 10.1038/s41392-022-01064-1.

6.肖卫民, 成蔚阳. 缺血性卒中神经保护剂治疗现状和研究展望[J]. 内科理论与实践, 2019, 14(5): 282-288. DOI: 10.16138/j.1673-6087.2019.05.004.

7.Savitz SI, Baron JC, Fisher M. Stroke Treatment Academic Industry Roundtable X: brain cytoprotection therapies in the reperfusion era[J]. Stroke, 2019, 50(4): 1026-1031. DOI: 10.1161/STROKEAHA.118.023927.

8.Xu J, Wang Y, Wang A, et al. Safety and efficacy of edaravone dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial[J]. Stroke Vasc Neurol, 2019, 4(3): 109-114. DOI: 10.1136/svn-2018-000221.

9.Xu J, Wang A, Meng X, et al. Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke: a phase III, randomized, double-blind, comparative trial[J]. Stroke, 2021, 52(3): 772-780. DOI: 10.1161/STROKEAHA.120.031197.

10.钟迪, 张舒婷, 吴波. 《中国急性缺血性脑卒中诊治指南2018》解读[J]. 中国现代神经疾病杂志, 2019, 19(11): 897-901. [Zhong D, Zhang ST, Wu B. Interpretation of "Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018"[J]. Chinese Journal of Modern Neurological Diseases, 2019, 19(11): 897-901.] DOI: 10.3969/j.issn.1672-6731.2019.11.015.

11.Kasner SE. Clinical interpretation and use of stroke scales[J]. Lancet Neurol, 2006, 5(7): 603-612. DOI: 10.1016/S1474-4422(06)70495-1.

12.中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国缺血性脑卒中和短暂性脑缺血发作二级预防指南2014[J]. 中华神经科杂志, 2015, 48(4): 258-273. DOI: 10.3760/cma.j.issn.1006-7876. 2015.04.003.

13.Xu X, Chen M, Zhu D. Reperfusion and cytoprotective agents are a mutually beneficial pair in ischaemic stroke therapy: an overview of pathophysiology, pharmacological targets and candidate drugs focusing on excitotoxicity and free radical[J]. Stroke Vasc Neurol, 2023, 13: svn-2023-002671. DOI: 10.1136/svn-2023-002671.

14.Hill MD, Goyal M, Menon BK, et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial[J]. Lancet, 2020, 395(10227): 878-887.DOI: 10.1016/S0140-6736(20)30258-0.

15.Wang C, Gu HQ, Dong Q, et al. Rationale and design of treatment of acute ischaemic stroke with edaravone dexborneol II (TASTE-2): a multicentre randomised controlled trial[J]. Stroke Vasc Neurol, 2024, 11: svn-2023-002938. DOI: 10.1136/svn-2023-002938.

16.Yamashita T, Sato T, Sakamoto K, et al. The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model[J]. Thromb Res, 2015, 135(6): 1209-1213. DOI: 10.1016/j.thromres.2015.04.011.

17.Fisher M, Savitz SI. Pharmacological brain cytoprotection in acute ischaemic stroke-renewed hope in the reperfusion era[J]. Nat Rev Neurol, 2022, 18(4): 193-202. DOI: 10.1038/s41582-021-00605-6.

18.李春颖, 鞠东升, 潘澍潇, 等. 依达拉奉右莰醇联合阿替普酶治疗急性缺血性脑卒中的疗效观察[J]. 中风与神经疾病杂志, 2023, 40(10): 936-938. [Li CY, Ju DS, Pan SY, et al. Efficacy of edaravone dextran combined with alteplase in the treatment of acute ischemic stroke[J]. Journal of Stroke and Neurological Disease, 2023, 40(10): 936-938.] DOI: 10.19845/j.cnki.zfysjjbzz.2023.0202.

19.谷亚伟, 楚旭, 赵路静, 等. 依达拉奉右莰醇在高龄中重度急性缺血性脑卒中rt-PA静脉溶栓治疗中的应用时机[J]. 山东医药, 2024, 64(2): 13-17. [Gu YW, Chu X, Zhao LJ, et al. Timing of edaravone dexborneol in intravenous thrombolysis with rt-PA for elderly patients with moderate to severe acute ischemic stroke[J]. Shandong Pharmaceuticals, 2024, 64(2): 13-17.] DOI: 10. 3969/j. issn.1002-266X. 2024. 02. 003.

20.Kobayashi S, Fukuma S, Ikenoue T, et al. Effect of edaravone on neurological symptoms in real-world patients with acute ischemic stroke[J]. Stroke, 2019, 50(7): 1805-1811. DOI: 10.1161/STROKEAHA.118.024351.

21.Zhang N, Komine-Kobayashi M, Tanaka R, et al. Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain[J]. Stroke, 2005, 36(10): 2220-2225. DOI: 10.1161/01.STR.0000182241.07096.06.

22.Li Y, Ren M, Wang J, et al. Progress in borneol intervention for ischemic stroke: a systematic review[J]. Frontiers Pharmacol, 2021, 12: 606682. DOI: 10.3389/fphar.2021.606682.

23.Wu HY, Tang Y, Gao LY, et al. The synergetic effect of edaravone and borneol in the rat model of ischemic stroke[J]. Eur J Pharmacol, 2014, 740: 522-531. DOI: 10.1016/j.ejphar.2014.06.035.